The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Adaptive Biotechnologies; Binding Site; Bristol-Myers Squibb; Celgene; Cellectis; Glenmark; Janssen; Juno Therapeutics; Pfizer
Research Funding - Amgen; Celgene; Glenmark; Janssen; Karyopharm Therapeutics; Seagen; Takeda
Other Relationship - Janssen; Merck; Takeda
Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study.
 
Sham Mailankody
Honoraria - Physicans' Education Resource; Weber Shandwick
Research Funding - Janssen Oncology (Inst); Juno Therapeutics (Inst); Takeda (Inst)
 
Meghan Salcedo
No Relationships to Disclose
 
Elizabet Tavitian
No Relationships to Disclose
 
Neha Korde
Research Funding - Amgen
 
Nikoletta Lendvai
Consulting or Advisory Role - Amgen; Karyopharm Therapeutics
Research Funding - Amgen; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi; Takeda
 
Hani Hassoun
No Relationships to Disclose
 
Alexander M. Lesokhin
Honoraria - Bristol-Myers Squibb; Celgene; Celldex; Genmab; Takeda
Consulting or Advisory Role - Aduro Biotech; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Sanofi (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Serametrix, Inc
 
Oscar Boutros Lahoud
No Relationships to Disclose
 
Eric L. Smith
Consulting or Advisory Role - Celgene; Fate Therapeutics
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Celgene
 
Malin Hultcrantz
Employment - Oticon (I)
Leadership - Oticon (I)
Honoraria - Cochlear (I); Oticon (I)
Consulting or Advisory Role - Cochlear (I); Medel (I); Oticon (I)
Research Funding - Cochlear (I); Oticon (I)
Patents, Royalties, Other Intellectual Property - Liber (I)
Travel, Accommodations, Expenses - Cochlear (I); Medel (I); Oticon (I)
 
Sean M. Devlin
No Relationships to Disclose
 
Ola Landgren
No Relationships to Disclose